ImaginAb Appoints Roger Crystal, MD as Vice President of Business Development
LOS ANGELES, SINGAPORE, and TOKYO, July 28, 2014 /PRNewswire/ -- ImaginAb, Inc. today announced today announced that it has appointed Roger Crystal, MD as Vice President of Business Development. Dr. Crystal most recently served in the Global Business Development Product Acquisition & Licensing team at G.E. Life Sciences.
"Roger's experience in developing business strategy and partnerships in the precision medicine space will be extremely valuable as we continue to partner with biotechnology and pharmaceutical companies across the spectrum to extend the reach of ImaginAb's capabilities," said Dr. Christian Behrenbruch, co-founder and CEO of ImaginAb. "We are very pleased to welcome Roger to Los Angeles and look forward to his contributions as a member of the ImaginAb executive team."
Prior to joining ImaginAb, Dr. Crystal served on the Global Business Development Product Acquisition & Licensing team at G.E. Life Sciences where he was responsible for evaluating in vivo and in vitro molecular and IT technologies for acquisitions, licensing or partnering deals. In this capacity he also managed pharmaceutical company engagements, out-licensing deals and commercialization partnerships for late stage molecular imaging agents including molecular imaging technologies. Dr. Crystal also has prior management consulting and corporate M&A experience from AT Kearney and Goldman Sachs.
"ImaginAb's proprietary antibody fragment technology has the potential to transform the way patients are staged and managed in cancer and immunology indications," commented Dr. Crystal. "I am enthusiastic to be joining ImaginAb, particularly at a time when the application of our products has the potential to further advance the tremendous progress being made in the immuno-oncology field."
Dr. Crystal holds degrees in Medicine and Physiology from the University of Birmingham and an MBA from the London Business School. Dr. Crystal began his career as a surgeon at University College Hospital London and is a member of the Royal College of Surgeons of England specializing in otolaryngology, most recently at St Mary's Hospital (Imperial College), London.
ImaginAb is redefining therapeutic management by harnessing the power of antibody technology for in vivo imaging. The company's proprietary antibody fragment platform yields actionable molecular information to guide treatment decisions in cancer and immunology. ImaginAb also collaborates with select biopharmaceutical partners to design imaging agents as companion diagnostics for therapeutic antibodies. ImaginAb's technology is positioned to deliver on the promise of precision medicine by improving patient outcomes and reducing the cost of healthcare.
For more information, visit www.imaginab.com.
SOURCE ImaginAb, Inc.